RORα suppresses interleukin-6-mediated hepatic acute phase response

Area of Science:

• Hepatology
• Immunology
• Molecular Biology

Background:

• Acute liver failure (ALF) involves liver dysfunction driven by the acute-phase response (APR).
• The interleukin-6 (IL-6) signaling pathway is a key driver of hepatic APR and acute-phase protein (APP) release.
• Current therapies targeting the IL-6-STAT3 pathway for ALF are limited.

Purpose of the Study:

• To investigate the role of nuclear receptor retinoic acid-related orphan receptor alpha (RORα) in regulating hepatic APR and ALF.
• To determine if RORα activation can mitigate liver injury mediated by the IL-6-STAT3 pathway.

Main Methods:

• Diethylnitrosamine-induced acute liver injury model in mice.
• Administration of JC1-40, a RORα activator.
• In vitro studies using primary hepatocytes.
• Analysis of APP expression (e.g., CXCL1, LCN2) and IL-6-STAT3 signaling pathway components.

Main Results:

• RORα activation by JC1-40 or adenoviral RORα infusion significantly reduced diethylnitrosamine-induced acute liver injury in mice.
• RORα activation repressed the transcriptional expression of key APPs, including CXCL1 and LCN2.
• Activation of RORα inhibited IL-6-mediated STAT3 activation in hepatocytes and decreased IL-6 receptor alpha expression.

Conclusions:

• RORα acts as a negative regulator of the hepatic IL-6-STAT3 signaling pathway.
• RORα activation demonstrates therapeutic potential for treating inflammatory ALF by limiting APR-mediated liver injury.
• RORα represents a novel therapeutic target for ALF associated with inflammatory conditions.